Cuba is one of the few countries in which the biotechnology industry works in full alliance with the Public Health system to control diseases that may pose epidemiological risks.In this sense, the Immunoassay Center (CIE), belonging to BioCubaFarma, works on the research and development of a rapid test for the detection of dengue.Rebeca González Fernández, institutional communicator of the CIE, told Granma that the Health system already uses the Umelisa IgM Dengue – a test developed by that Center – which requires processing in a laboratory with Ultra Microanalytical System (SUMA) technology, and must be Wait until the patient’s fifth day of symptoms to perform it.For this reason, she expressed, the CIE took on the task of working on a rapid test, the results of which are available in a short time, because it detects the NS1 antigen in the first hours of the disease.”This will allow the National Health System to take all focus control measures in a febrile patient, immediately upon confirmation of dengue,” she highlighted.Within its conception – she said – it is expected that it will be easy to interpret and use at any level of the Health system.González Fernández highlighted that this would be the first rapid test that the CIE will develop with a greater percentage of its own technology, since the Sumasof diagnostic device already exists, which detects the presence of human hemoglobin in feces, and is used in Cuba as a screening in the colon cancer, for adults over 50 years of age.He reiterated that the Center is working to achieve the rapid dengue detection test in the shortest possible time, but it is a rigorous process that is developed in stages and includes registration by the Center for State Control of Medicines, Equipment and Devices Doctors (Cecmed).As it is still in its early stages, the test does not have a name, however, González Fernández pointed out that it will surely be in relation to the SUMA brand that houses all the Center’s products.
Source: Granma Newspaper
Views: 0
